Evolus, Inc (EOLS)

Etorro trading 970x250
Evolus, Inc (EOLS) Logo

About Evolus, Inc

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660

Evolus, Inc News and around…

Latest news about Evolus, Inc (EOLS) common stock and company :

Relative Strength Alert For Evolus
04 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Interesting EOLS Put And Call Options For April 2022
29 Sep, 2021 FinancialContent

Investors in Evolus Inc (EOLS) saw new options become available this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

What Kind Of Shareholders Own Evolus, Inc. (NASDAQ:EOLS)?
23 Sep, 2021 Yahoo! Finance

If you want to know who really controls Evolus, Inc. ( NASDAQ:EOLS ), then you'll have to look at the makeup of its...

Evolus Announces Participation in September Investment Conferences
02 Sep, 2021 FinancialContent
4 Stocks Insiders Are Buying
26 Aug, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

12 Health Care Stocks Moving In Monday's After-Market Session
23 Aug, 2021 FinancialContent

Gainers Cara Therapeutics (NASDAQ:CARA) stock rose 22.54% to $17.5 during Monday's after-market session. Trading volume for this ...

When Will Evolus, Inc. (NASDAQ:EOLS) Become Profitable?
09 Aug, 2021 Yahoo! Finance

Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...

First Week of September 17th Options Trading For Evolus
05 Aug, 2021 FinancialContent

Investors in Evolus Inc (EOLS) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EOLS options chain for the new September 17th contracts and identified one put and one call contract of particular interest.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus Reports Second Quarter 2021 Results and Provides Business Update
04 Aug, 2021 FinancialContent
Sum Up The Parts: DWAS Could Be Worth $96
03 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.40 per unit.

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
28 Jul, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus to Report Second Quarter 2021 Results and Provide Business Update
22 Jul, 2021 FinancialContent
Can Evolus Disrupt the Botox Market?
03 Jul, 2021 FinancialContent

This small-cap stock is going after a billion-dollar market.

Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations
30 Jun, 2021 FinancialContent
Peek Under The Hood: PTH Has 21% Upside
28 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $203.66 per unit.

Did Business Growth Power Evolus' (NASDAQ:EOLS) Share Price Gain of 149%?
25 Jun, 2021 Yahoo! Finance

Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...

Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color
24 Jun, 2021 FinancialContent
How The Parts Add Up: DWAS Targets $96
27 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $95.85 per unit.

Evolus Appoints Dan Stewart as Vice President and General Manager, International
19 May, 2021 FinancialContent
Evolus Reports First Quarter 2021 Results and Provides Business Update
12 May, 2021 FinancialContent
Evolus, Inc. to Host Earnings Call
12 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Evolus, Inc. (NASDAQ:EOLS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 4:30 PM Eastern Time.

Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events
12 May, 2021 FinancialContent

Evolus Inc(NASDAQ:EOLS) hasannounced two newly published peer review studies in Aesthetic Surgery Journalthat ...

Aesthetic Surgery Journal Publishes Long Term Safety and Efficacy Data of Jeuveau® for the Treatment of Moderate to Severe Frown Lines
12 May, 2021 FinancialContent
Earnings Scheduled For May 12, 2021
12 May, 2021 FinancialContent

Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first ...

Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
11 May, 2021 Yahoo! Finance

Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.

Evolus is Now Oversold (EOLS)
10 May, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Why Evolus (EOLS) Might Surprise This Earnings Season
10 May, 2021 Yahoo! Finance

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Evolus to Report First Quarter 2021 Results and Provide Business Update
04 May, 2021 FinancialContent
Evolus to Participate in the 7th Annual Truist Securities Life Sciences Summit
29 Apr, 2021 FinancialContent

Evolus, Inc (EOLS) is a NASDAQ Common Stock listed in , ,

970x250